Toscafund's £1bn Spire Bid Reshapes Private Healthcare

What Toscafund is proposing, and why the board said yes

Spire Healthcare (LSE: SPI) confirmed on 14 May 2026 that it had received a non-binding proposal from funds advised by Toscafund Asset Management to acquire the entire issued share capital at 250p per share, according to the company's announcement. The offer values the group at approximately £1bn.

Toscafund is already Spire's second-largest shareholder. The hedge fund, founded by Martin Hughes, a City figure known as "the Rottweiler" for his combative activist style, has a track record of building significant stakes in UK-listed companies it considers undervalued, as reported by the Guardian. Hughes has historically favoured situations where he sees structural value that public markets have failed to price in.

Spire's board said it had reviewed the proposal and was willing to recommend it to shareholders, subject to the usual conditions around due diligence and a formal offer. The share price reaction was immediate: Spire's stock surged by nearly 50% on the day, according to the Guardian's report, suggesting the market had been pricing the company well below the level at which Toscafund sees value.

The gap between the pre-announcement trading price and the 250p offer is significant. Spire shares had been trading at depressed levels relative to the company's asset base and earnings trajectory, reflecting broader market scepticism about UK mid-cap healthcare operators. The board's willingness to back the approach at this price signals that directors believe the public market discount had become entrenched.

This is not the first time Spire has attracted acquisition interest. In 2021 and 2022, Ramsay Health Care, the Australian hospital group, pursued a bid for Spire but ultimately walked away. The failure of that earlier approach left Spire as an independent listed operator in a sector that has since seen significant demand growth.

Spire's position in UK private healthcare

Spire operates 39 hospitals and eight clinics across England, making it the largest private hospital group in the UK by number of sites. Its portfolio includes well-known facilities such as the Claremont Hospital in Sheffield and St Anthony's Hospital in south London, as noted in the company's public filings.

The company sits at the intersection of two powerful demand drivers. NHS waiting lists in England remain above 7 million, according to NHS England data, creating sustained overflow demand for privately funded treatment. Simultaneously, private medical insurance uptake has been rising as employers and individuals seek faster access to elective procedures.

For Spire, this has translated into revenue growth. The group has benefited from a structural shift in patient volumes, with both self-pay and insured patients turning to private hospitals for procedures such as hip and knee replacements, cataract surgery, and diagnostic imaging. NHS-funded work, where private hospitals treat NHS patients under contract, has also remained a meaningful revenue stream.

Yet the share price before Toscafund's approach suggested the market was not fully crediting this demand picture. Several factors may explain the discount: concerns about NHS contract margins, rising staffing costs across the healthcare sector, and the overhang of capital expenditure needed to maintain ageing hospital estates. A take-private structure would remove the obligation to manage quarterly earnings expectations and allow the new owner to invest on longer time horizons.

What a take-private means for the sector's competitive dynamics

If completed, the Toscafund deal would remove the UK's largest private hospital operator from public markets and place it under the control of an activist hedge fund with a concentrated investment thesis. The implications for the broader sector extend well beyond Spire's own operations.

First, there is the question of pricing power. A privately held Spire, freed from public market scrutiny of margins, could pursue more aggressive pricing strategies with insurers and NHS commissioners. For mid-market operators and smaller private hospital groups competing for the same patient volumes, this could compress margins or force consolidation.

Second, the deal signals that activist capital sees structural undervaluation in UK private healthcare assets. Other listed or privately held operators may find themselves subject to similar approaches. The sector has already seen private equity interest in adjacent areas such as diagnostics, fertility services, and primary care; a take-private of this scale in acute hospital care raises the stakes.

Third, there is the regulatory dimension. The Competition and Markets Authority would scrutinise any transaction that concentrates ownership in a sector where patient choice and NHS commissioning are intertwined. Toscafund's existing stake means the CMA will need to assess whether common ownership of this scale alters competitive dynamics in local hospital markets.

"Spire Healthcare said it had received a non-binding proposal worth 250p a share from funds advised by the activist investor Toscafund Asset Management," the Guardian reported.

For NHS trusts that rely on private-sector capacity to manage waiting lists, the identity of the ultimate owner matters. A hedge-fund-led ownership structure typically prioritises return on capital over long-term capacity building, which could affect the willingness to invest in new theatres, beds, or workforce development.

Questions operators and boards should be asking

The Toscafund approach to Spire is not simply a City transaction. It is a signal about where capital sees opportunity in UK healthcare, and it carries implications for anyone running or governing a health or care business.

For private hospital operators, the immediate question is whether the deal, if completed, will alter the competitive landscape in their local markets. Spire's pricing, referral relationships, and NHS contracting terms could all shift under new ownership.

For NHS-outsourcing partners, the question is about continuity. Private operators that hold NHS contracts are subject to regulatory and quality standards, but ownership changes can bring new management priorities. Boards of organisations that subcontract to, or compete with, Spire should be stress-testing their assumptions about market structure.

For boards of listed healthcare companies, the Spire situation illustrates the vulnerability of mid-cap operators trading at a discount to intrinsic value. If the public market consistently undervalues healthcare assets relative to private capital's assessment, more take-privates will follow. Directors should consider whether their own capital structures and shareholder registers leave them exposed to similar approaches.

Finally, for policymakers and regulators, the deal raises a broader question about the ownership of essential health infrastructure. The UK has debated the role of private equity in care homes, GP surgeries, and dental chains. A hedge-fund-led acquisition of the country's largest private hospital group adds a new chapter to that conversation.

The proposal remains non-binding, and a formal offer has not yet been made. The coming weeks will determine whether Toscafund proceeds to a firm bid and whether any competing interest emerges. What is already clear is that the deal has reframed the discussion about who owns, and who profits from, the UK's growing reliance on private healthcare capacity.